Pandor, A. (Abdullah), Eggington, S., Paisley, S., Tappenden, P. (Paul), 1980- and Sutcliffe, Paul A.. (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer : systematic review and economic evaluation. Health Technology Assessment, Vol.10 (No.41). pp. 1-204. ISSN 1366-5278

Preview	Text WRAP_Sutcliffe_Clinical_cost_effectiveness.pdf - Published Version Download (1592Kb) | Preview
Preview	Text (Coversheet) WRAP_Sutcliffe_Clinical_cost_effectiveness_coversheet_.pdf - Supplemental Material Download (49Kb) | Preview

Abstract

Objectives: To assess the clinical and cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5-FU/LV), and capecitabine monotherapy (within their licensed indications), as adjuvant therapies in the treatment of patients with Stage III (Dukes’ C) colon cancer after complete surgical resection of the primary tumour, as compared with adjuvant chemotherapy with an established fluorouracil-containing regimen. Data sources: Ten electronic bibliographic databases were searched from inception to January 2005. Searches were supplemented by hand searching relevant articles, sponsor and other submissions of evidence to the National Institute of Health and Clinical Excellence and conference proceedings. Review methods: A systematic review and meta-analysis (where appropriate) of clinical efficacy evidence and a cost-effectiveness review and economic modelling were carried out. Marginal costs, life years gained and cost-effectiveness acceptability curves were estimated. Probabilistic sensitivity analysis was used to generate information on the likelihood that each of the interventions was optimal. Results: Three randomised active-controlled trials, of varying methodological quality, were included in the review. The MOSAIC trial and NSABP C-07 study considered the addition of oxaliplatin to adjuvant treatment (albeit administered in different 5-FU/LV regimens) and the X-ACT study compared oral capecitabine with bolus 5-FU/LV alone. A review of the available evidence indicated that in patients with Stage III colon cancer, oxaliplatin in combination with an infusional de Gramont schedule of 5-FU/LV (FOLFOX4) was more effective in preventing and delaying disease recurrence than infusional 5-FU/LV alone (de Gramont regimen). Serious adverse events and treatment discontinuations due to toxicity were more evident with oxaliplatin-based regimens (FOLFOX4 and FLOX regimen) than infusional or bolus 5-FU/LV alone (de Gramont and Roswell Park regimen). Oral capecitabine was at least equivalent in disease-free survival to the bolus Mayo Clinic 5-FU/LV regimen for patients with resected Stage III colon cancer. Although, the safety and tolerability profile of capecitabine was superior to that of the Mayo Clinic 5-FU/LV regimen, it has not been evaluated in comparison with other less toxic 5-FU/LV regimens currently in common use in the UK. Based on the assumptions and survival analysis methods used, the cost-effectiveness analysis using economic modelling estimated that capecitabine was a dominating strategy and resulted in a cost-saving of approximately £3320 per patient in comparison with the Mayo Clinic 5-FU/LV regimen, while also providing an additional 0.98 quality-adjusted life-years (QALYs) over a 50-year model time horizon. Oxaliplatin in combination with 5-FU/LV (FOLFOX4 regimen) is estimated to cost an additional £2970 per QALY gained when compared with the de Gramont 5-FU/LV regimen and demonstrated superior survival outcomes with marginal costs. The uncertainty analysis suggests that both interventions have a high probability of being cost-effective at a threshold of both £20,000 and £30,000. An indirect comparison of the FOLFOX4 and Mayo Clinic 5-FU/LV regimens suggests that the use of FOLFOX4 in place of the Mayo Clinic 5-FU/LV regimen would cost an additional £5777 per QALY gained. An incremental cost-effectiveness ratio (ICER) is estimated to be approximately £13,000 per QALY gained from treatment with FOLFOX4 compared with capecitabine. However, if the Mayo Clinic and the de Gramont 5-FU/LV regimens are assumed to be equivalent in terms of effectiveness, the ICER of FOLFOX4 in comparison with capecitabine may be greater than £30,000 per QALY. Conclusions: The evidence suggests that both capecitabine and FOLFOX4 are clinically effective and cost-effective in comparison with 5-FU/LV regimens (Mayo Clinic and de Gramont schedules). Further research is suggested into the effectiveness, tolerability, patient acceptability and costs of different oxaliplatin/fluoropyrimidine schedules in the adjuvant setting; the effects of treatment duration on efficacy; adverse events; resource data collection strategies and reporting of summary statistics; subgroups benefiting most from adjuvant chemotherapy; and methods for estimating mean survival.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Colon (Anatomy) -- Cancer -- Treatment, Oxaliplatin
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	November 2006
Volume:	Vol.10
Number:	No.41
Page Range:	pp. 1-204
Identification Number:	10.3310/hta10410
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Cooper N, Gautrey M, Quinn M, Cancer registrations in England, 2002. London: Office for National Statistics; 2005. 2. Welsh Cancer Intelligence and Surveillance Unit. 2005 triennial report: cancer incidence, mortality and survival in Wales. Cardiff: Welsh Cancer Intelligence and Surveillance Unit; 2005. 3. Cancer Research UK. Large bowel (colorectal) cancer factsheet, April 2005. URL: http://www.cancerresearchuk.org/aboutcancer/ statistics/factsheets/?version=2. Accessed 2 July 2005. 4. Rowan S, Wood H, Cooper N, Quinn M. Update to cancer trends in England and Wales 1950–1999. London: Office for National Statistics; 2005. 5. Reddy B, Engle A, Katsifis S, Simic B, Bartram HP, Perrino P, et al. Biochemical epidemiology of colon cancer: effect of types of dietary fiber on fecal mutagens, acid, and neutral sterols in healthy subjects. Cancer Res 1989;49:4629–35. 6. Potter JD. Reconciling the epidemiology, physiology, and molecular biology of colon cancer. JAMA 1992;268:1573–7. 7. Willett W. The search for the causes of breast and colon cancer. Nature 1999;338:389–94. 8. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess in press. 9. Mason P. Colorectal cancer – the disease and its management. Hosp Pharm 2004;11:175–7. 10. National Institute for Health and Clinical Excellence. National Institute for Health and Clinical Excellence guidance on cancer services: improving outcomes in colorectal cancers (manual update). London: NICE; 2004. 11. Bishop DT, Hall NR. The genetics of colorectal cancer. Eur J Cancer 1994;30A:1946–56. 12. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–7. 13. Cummings JH, Bingham SA. Diet and the prevention of cancer. BMJ 1998;317:1636–40. 14. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a metaanalysis. Gut 2002;48:526–35. 15. Michels KB, Giovannucci E, Joshipura KJ, Rosner BA, Stampfer MJ, Fuchs CS, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000;92:1740–52. 16. Asano TK, McLeod RS. Non steroidal antiinflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2004; Issue 1; CD004079. 17. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev 2002;11:535–42. 18. Van Cutsem E, Kataja W. ESMO Minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann Oncol 2005;16:i16–i17. 19. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition staging. J Natl Cancer Inst 2004;96:1420–5. 20. Roche Products Limited. Roche sponsor submission to the National Institute for Health and Clinical Excellence: Xeloda® (capecitabine) NICE submission – achieving clinical excellence in the adjuvant treatment of colorectal cancer. Roche Products Limited, UK; 2005. 21. South West Cancer Intelligence Service. Data held on file: audit study of patients with colorectal cancer undertaken in the Wessex region 1991–1995. South West Cancer Intelligence Service, Bristol, 1995. 22. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003;7(32). 23. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II cancer. J Clin Oncol 2004;22:3408–19. 24. Cancer Research UK. Large bowel (colorectal) cancer factsheet, April 2004. URL: http://www.cancerresearchuk.org/aboutcancer/ statistics/statsmisc/pdfs/factsheet_bowel_ apr2004.pdf. Accessed 2 July 2005. 25. Cancer Research UK. Cancer stats – mortality UK February 2004. URL: http://info.cancerresearchuk.org/images/ publicationspdfs/cancerstats_mortality.pdf. Accessed 2 July 2005. 26. Royal College of Nursing. External submission to the National Institute for Health and Clinical Excellence by the Royal College of Nursing. 2005. 27. Patel K, Anthoney DA, Crellin AM, Sebag- Montefiore D, Messruther J, Seymour MT. Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 2004;15:568–73. 28. Scottish Intercollegiate Guidelines Network (SIGN). Management of colorectal cancer – Guidance No. 67. Edinburgh: Scottish Intercollegiate Guidelines Network; 2003. 29. Kerr DJ, Gray R, McConkey C, Barmwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules. QUASAR Colorectal Cancer Study Group. Ann Oncol 2000; 11:947–55. 30. Association of Coloproctology of Great Britain and Ireland. Association of Coloproctology of Great Britain and Ireland guidelines for the management of colorectal cancer (2001). London: Royal College of Surgeons; 2001. 31. Atkin W. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359:1291–300. 32. Rowan S, Gautrey M, Quinn MJ. Cancer registrations in England, 2001. London: National Cancer Intelligence Centre, Office for National Statistics; 2004. 33. Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence in Wales 1992–2001. Cardiff: Welsh Cancer Intelligence and Surveillance Unit; 2004. 34. Cassidy J. Capecitabine vs bolus 5-FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial. Presented at the ASCO Annual Meeting, 2004. 35. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surgic Oncol 2001;8:347–53. 36. Seymour M. Optimizing the use and sequencing of fluorouracil and oxaliplatin in advanced colorectal cancer (ACRC): the UK MRC FOCUS (CR08) Trial. Ann Oncol 2004;15(Suppl 3):2. 37. Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997;40:35–41. 38. Sanofi-Aventis. Eloxatin – summary of product characteristics. Electronic medicines compendium. Sanofi-Aventis, UK; 2005. 39. Roche Products Limited. Xeloda – Summary of product characteristics. Electronic medicines compendium. Roche Products Limited, UK; 2005. 40. Joint Formulary Committee. British National Formulary 49. British Medical Association and Royal Pharmaceutical Society of Great Britain; London; 2005. 41. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. University of York, York: NHS Centre for Reviews and Dissemination; 2001. 42. Altman D, Andersen P. Calculating the number to treat for trials where the outcome is time to an event. BMJ 1999;319:1492–5. 43. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34. 44. Higgins JP, Thompson SG, Deeks JJ, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60. 45. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51. 46. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. ASCO Annual Meeting, 2005; Abstract No. LBA3500. 47. de Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median followup of 4 years. ASCO Gastrointestinal Cancers Symposium – Colon and Rectum, 2005; Abstract No. 167. 48. de Gramont A. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Presented at ASCO Gastrointestinal Cancers Symposium – Colon and Rectum, 2005. 49. de Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median followup of 4 years. ASCO Annual Meeting, 2005; Abstract No. 3501. 50. de Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in stage II and III colon cancer: updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial. Ann Oncol 2004;15:275PD. 51. de Gramont A. MOSAIC adjuvant trial. Colorectal Cancer Update 2004;3:1–3. 52. de Gramont A, Banzi M, Navarro M, Tabernero J, Hickish T, Bridgewater J, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: results of the international randomized MOSAIC trial. Onkologie 2003;26:Abstract No. 1015. 53. de Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: safety results of the international randomized MOSAIC trial. Onkologie 2002;25:Abstract No. 525. 54. Hickish T, Boni C, Navarro M, Tabernero J, Topham C, Bonetti A, et al. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): subpopulation data from the MOSAIC trial. J Clin Oncol 2004;22:Abstract No. 3619. 55. Hickish T, Boni C, Tabernero J, Clingan P, Colucci G, Nowacki M, et al. Oxaliplatin/5- fluorouracil/leucovorin in stage II and III colon cancer: updated results of the international randomized MOSAIC trial. ASCO Gastrointestinal Cancers Symposium – Colon and Rectal Cancers 2004; Abstract No. 211. 56. Hickish T, Boni C, Navarro M, Tabernero J, Bonetti A, Clingan P, et al. Stage II patients in the MOSAIC trial evaluating oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis. Ann Oncol 2004;15:284P. 57. Sanofi-Synthelabo. Eloxatin™ (oxaliplatin for injection) prescribing information 2004. URL: http://www.eloxatin.com/eloxatinpi.pdf. Accessed 1 March 2005. 58. Tabah-Fisch I, Maindrault-Goebel F, Benavides M, Zaniboni A, Bigelow R, Bleiberg H. Oxaliplatin/5FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients. ASCO Annual Meeting, 2002; Abstract No. 556. 59. Topham C, Boni C, Navarro M, Hickish T, Tabernero J, Bonetti A, et al. Multicenter international randomized study of oxaliplatin/5FU/LV (folfox) in stage II and III colon cancer (MOSAIC trial): final results. Eur J Cancer 2003;1:S324–5. 60. Wolmark N. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. Presented at ASCO Annual Meeting, 2005. 61. de Gramont A, Schmoll HJ, Cervantes A, Tournigand C. The evolving role of oxaliplatin in the management of colorectal cancer. Colorectal Dis 2003;5:10–19. 62. Maung K, Chu E, Jain VK. Update on adjuvant trials in the treatment of high-risk colorectal cancer. Clin Colorectal Cancer 2004;3:211–14. 63. National Cancer Institute. National Cancer Institute physician data query (PDQ) database phase III study of fluorouracil and leucovorin calcium with or without oxaliplatin in patients with Stage II or III carcinoma of the colon. URL: http://www.cancer.gov/clinicaltrials/NSABP-C-07, 2005. Accessed 21 June 2005. 64. Smith RE, Colangelo L, Wieand S, Kuebler JP, Pazdur R, Begovic M, et al. The occurrence of severe enteropathy among patients with stage II/III resected colon cancer (CC) treated with 5-FU/leucovorin (FL) plus oxaliplatin (FLOX). Proc Am Soc Clin Oncol 2003;22:Abstract No. 1181. 65. Coppola FS, Arca R, Ferro A, Delfino C, Blajman C, Richardet E, et al. A Phase III trial (colo-oxalad) of adjuvant therapy for very high risk colon cancer (CC) patients (PTS) with oxaliplatin (OXA) = bolus 5-fluorouracil (5-FU)/folinic acid (FA): a toxicity report. Onkologie 2002;25:Abstract No. 656. 66. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Methodol Rev 2005; Issue 2; MR000005. 67. Khan KS, Kunz R, Kleijnen J, Antes G. Systematic reviews to support evidence-based medicine – how to review and apply findings of healthcare research. London: Royal Society of Medicine Press; 2003. 68. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408–12. 69. Andre T, de Gramont, A. An overview of adjuvant systemic chemotherapy for colon cancer. Clin Colorectal Cancer 2004;4:S22–8. 70. Sargent DJ, Wieand S, Benedetti J, Labianca R, Haller DG, Shepherd LE, et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed). 2004; 22:Abstract No. 3502. 71. Flemming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125:605–13. 72. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431–40. 73. Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004;350:2406–8. 74. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated May 2005]. Cochrane Library. 2005. 75. Heritier SR, Gebski V, Keech AC. Inclusion of patients in clinical trial analysis: the intention-totreat principle. Med J Aust 2003;179:438–40. 76. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36–9. 77. Messori A, Becagli P, Trippoli S. Median versus mean lifetime survival in the analysis of survival data. Haematologica 1997;82:730. 78. Rougier P, Mitry E, Aranda E, Daniele B, Labianca R, Carrato A. Elderly colorectal cancer patients are under treated. Eur J Cancer Suppl 2004;2:8–13. 79. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001;12:435–42. 80. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091–7. 81. Au HJ, Mulder KE, Fields ALA. Systematic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer 2003;3:165–71. 82. Mahoney T, Kuo YH, Topilow A, Davis JM. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 2000; 135:182–5. 83. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93:850–7. 84. Chau I, Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat Rev 2002;28:223–36. 85. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;136:349–57. 86. Maxwell-Armstrong C, Scholefield J. Colorectal cancer. Clin Evid 2004;11:562–70. 87. Gill S, Loprinzi CL, Sargent DJ, Thorne SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797–806. 88. Andre T, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21:2896–903. 89. Macdonald JS. Continuous low-dose infusion of fluorouracil: is the benefit worth the cost? J Clin Oncol. 1989;7:412–14. 90. Gill S, Thomas RR, Goldberg RM. Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther 2003;18:683–92. 91. Waters C. Colorectal cancer – drug treatment. Hosp Pharm 2004;11:179–92. 92. British Oncology Pharmacy Association. External submission to the National Institute for Health and Clinical Excellence by the British Oncology Pharmacy Association. British Oncology Pharmacy Association, UK; 2005. 93. Louvet C, de Gramont A. Colorectal cancer: integrating oxaliplatin. Curr Treat Options Oncol 2003;4:405–11. 94. de Gramont A, Cervantes A, Andre T, Figer A, Lledo G, Flesch M, et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. J Clin Oncol (Meet Abstr) 2004;22:Abstract No. 3525. 95. Chau I, Cunningham, D. Oxaliplatin for colorectal cancer in the United States: better late than never. J Clin Oncol 2003;21:2049–51. 96. Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338–42. 97. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001;37:1000–5. 98. Andre T, Figer A, Cervantes A, Lledo G, Flesch M, Maindrault-Goebel F, et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized OPTIMOX study. Proc Am Soc Clin Oncol 2003;22:Abstract No. 1016. 99. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128–35. 100. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002;29:11–20. 101. Grothey A. Oxaliplatin – safety profile: neurotoxicity. Semin Oncol 2003;30:5–13. 102. Rothwell PM. Subgroup analysis in randomised controlled trial: importance, indications and interpretation. Lancet 2005;365:176–86. 103. Cook DI, Gebski V, Keech AC. Subgroup analysis in clinical trials. Med J Aust 2004;180:289–91. 104. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356–63. 105. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, C-04). J Clin Oncol 1999;17:1349–55. 106. Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum; Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol. 2004;22:484–92. 107. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-based Care’s Gastrointestinal Cancer Disease Site Group. J Clin Oncol. 2004;22:3395–407. 108. Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696–704. 109. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns, WI, Burris HA, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735–43. 110. Cassidy J, Twelves C, Nowacki M, Borner M, Cervantes A, Diaz-Rubio E, et al. Improved safety of capecitabine versus bolus 5-fluorouracil/ leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study). Presented at ASCO Gastrointestinal Cancers Symposium – Colon and Rectal Cancers, 2004. 111. Cassidy J, Koralewski P, Husseini F, Twelves C. Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for Dukes C colon cancer: no differences in treatment arms that could influence survival outcome. ASCO Annual Meeting – Gastrointestinal (Colorectal) Cancer Session, 2005; Abstract No. 3586. 112. Cassidy J, Scheithauer W, McKendrick J, Kroning H, Nowacki MP, Seitz JF, et al., on behalf of X-act Study Investigators. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. J Clin Oncol 2004;22:Abstract No. 3509. 113. Cassidy, J. The Xeloda® in Adjuvant Colon Cancer Therapy Trial. Colorectal Cancer Update 2004;1–3. 114. Diaz-Rubio E, Burris H, Douillard JY, Coxon FY, Maughan T, Bertetto O, et al., on behalf of the X-Act Study Group. Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). J Clin Oncol, 2004 ASCO Ann Meet Proc (Post-Meet Ed). 2004;22:Abstract No. 3737. 115. Douillard JY, Twelves C, McKendrick J, Bertetto O, Coxon F, Diaz-Rubio E, et al. Pharmacoeconomic analysis of capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes’ C colon cancer. Ann Oncol 2004;15:274PD. 116. McKendrick JJ, Cassidy J, Chakrapee-Sirisuk S, Fountzilas G, Iveson T, Jelic S, et al. Capecitabine (X) is resource saving compared with i.v. bolus 5-FU/LV in adjuvant chemotherapy for Dukes’ C colon cancer patients: medical resource utilization (MRU) data from a large phase III trial (X-ACT). J Clin Oncol 2004;22:Abstract No. 3578. 117. McKendrick J. Capecitabine (X) is resource saving compared with i.v. bolus 5-FU/LV in adjuvant chemotherapy for Dukes’ C colon cancer patients: medical resource utilization (MRU) data from a large phase III trial (X-ACT). Presented at ASCO Annual Meeting, 2004. 118. McKendrick J, Cassidy J, Van Hazel G, Twelves C, Wong A, Nowacki M, et al. Positive efficacy results of the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Ann Oncol 2004; 15:276PD. 119. Nowacki M, Kroening H, Cervantes A, Husseini F, McKendrick J, Schuller J, et al. Improved safety of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study). Eur J Cancer 2003;1:S326. 120. Rough A, MacLeod A, Cassidy J, McDonald L. Questionnaire audit assessing compliance in colon cancer patients (pts) taking adjuvant capecitabine (X) as part of the X-ACT trial. Ann Oncol 2004; Suppl. 3:Abstract 283P. 121. Twelves C, Wong A, Nowacki M, Cassidy J, Cervantes A, Koralewski P, et al., on behalf of X-ACT Study Investigators. Improved safety results of a ph III trial of capecitabine vs bolus 5- FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT Study). Proc Am Soc Clin Oncol 2003;22:Abstract No. 1182. 122. Twelves C, Wong A, Nowacki M, McKendrick J, Van Hazel G, Douillard J, et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes? C colon cancer. ASCO Annual Meeting – Gastrointestinal (Colorectal) Cancer Session, 2005; Abstract No. 3521. 123. Lassere Y, Hoff P. Management of hand–foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004;8 Suppl 1:S31–40. 124. Juni P, Altman D, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323:42–6. 125. Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. Med J Aust 2002; 177:256–7. 126. Walko CM. Capecitabine: a review. Clin Ther 2005; 27:23–44. 127. Gerbrecht BM. Current Canadian experience with capecitabine: partnering with patients to optimize therapy. Cancer Nurs 2003;26:161–7. 128. Marse H, Van Cutsem E, Grothey A, Valverde S. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004;8:S16–30. 129. Marshall JL. New therapies in the adjuvant setting for colon cancer. Business Briefing: North American PharmacoTherapy 2004;2:99–100. 130. Faithfull S, Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. European Journal of Oncology Nursing 2004;8 Suppl 1:S54–62. 131. Allegra C, Sargent DJ. Adjuvant therapy for colon cancer – the pace quickens. N Engl J Med 2005; 352:2746–8. 132. Saltz L. Advances in the management of colorectal cancer: Proceedings from ASCO 2004. URL: http://professional.cancerconsultants.com/ conferencecoverage.aspx?id=31094. Accessed 1 June 2005. 133. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349–58. 134. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110–15. 135. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992;35:1505–9. 136. Efficace F, Bottomley A, Vanvoorden V, Blazeby JM. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 2004; 40:187–97. 137. Chau I, Cunningham D. Chemotherapy in colorectal cancer: new options and new challenges. Br Med Bull 2002;64:159–80. 138. Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16:549–57. 139. Poplin EA, Benedetti J, Estes N, Haller DG, Mayer RJ, Goldberg RM, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005;23:1819–25. 140. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5- FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;88:1859–65. 141. Sobrero AF. Scheduling of fluorouracil: a forgetme- not in the jungle of doublets. J Clin Oncol 2004;22:4–6. 142. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higherdose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000;355:1588–96. 143. Sanofi-Aventis. Sanofi-Aventis sponsor submission to the National Institute for Health and Clinical Excellence: Eloxatin® (oxaliplatin) for the adjuvant treatment of colon cancer. Sanofi-Aventis, UK; 2005. 144. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart, GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. 145. Koperna T, Semmler D. Innovative chemotherapies for stage III colon cancer: A costeffectiveness study. Hepatogastroenterology 2003; 50:1903–9. 146. Aballea S, Chancellor J, Raikou M, Drummond M, Weinstein M, Brouard R, et al. Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of colon cancer in the US. ASCO Gastrointestinal Cancers Symposium – Colon and Rectum, 2005; Abstract No. 194. 147. Douillard JY, Twelves C, McKendrick JJ, Bertetto O, Diaz-Rubio E, Duffour J, et al. Pharmacoeconomic analysis of oral capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with i.v. 5-FU/LV in patients with Duke’s C colon cancer. Poster presented at the European Society for Medical Oncology (ESMO) Congress; October–November 2004, Vienna; Poster No. 274. 148. Monz BU, Konig HH, Leidl R, Staib L, Link KH. Cost-effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany. PharmacoEconomics 2003;21:709–19. 149. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma. Ann Intern Med 1995;122:321–6. 150. Ramsey SD, Andresen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88:1294–303. 151. Department of Health. National tariff, 2005–06, 2004. URL: http://www.dh.gov.uk/assetRoot/04/09/ 15/32/04091532.xls. Accessed 12 January 2005. 152. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Nat Cancer Inst 1996; 88:1039–45. 153. Department of Health. NHS reference costs 2003 and national tariff 2004 (payment by results core tools 2004), 2004. URL: http://www.dh.gov.uk/ assetRoot/04/07/01/16/04070116.xls. Accessed 12 January 2005. 154. Sanofi-Aventis. Addendum to Sanofi-Aventis submission to the National Institute for Health and Clinical Excellence: Eloxatin® (oxaliplatin) for the adjuvant treatment of colon cancer. Sanofi-Aventis, UK; 2005. 155. Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and costeffectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001;5(25). 156. Government Actuary’s Department. Interim life tables for England and Wales (2001–2003), 2005. URL: http://www.gad.gov.uk. Accessed 1 June 2005. 157. Medical Research Council. Fluorouracil, oxaliplatin and irinotecan: use and sequencing (FOCUS): clinical protocol. London: Medical Research Council; 2003; CR08. 158. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37. 159. Staib L, Link KH, Blatz A, Beger HG. Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients – monoinstitutional experience. World J Surg 2002;26:59–66. 160. McDermott FT, Hughes ESR, Pihl E, Milne BJ, Price AB. Comparative results of surgical management of single carcinomas of the colon and rectum: a series of 1939 patients managed by one surgeon. Br J Surg 1981;68:850–5. 161. Pihl E, Hughes ESR, McDermott FT, Milne BJ, Korner JMN, Price AB. Cancer specific long-term survival. A series of 615 patients treated by one surgeon. Ann Surg 1980;192:114–17. 162. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Nat Cancer Inst 2004;96:1128–32. 163. Ferlay J, Bray F, Sankila R, Parkin DM. EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1998, version 5.0. IARC Cancer Base No. 4. Lyon: IARC Press, 1999. 164. Quinn M, Babb P. Cancer trends in England and Wales 1950–1999. No. 66. Stationery Office: London; 2001. 165. Curtis L, Netten A. Unit costs of health and social care. Canterbury: University of Kent; 2004. 166. Boland A, Haycox A, Bagust A, Fitzsimmons L. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technol Assess 2003;7(36). 167. Netten A, Dennett J, Knight J. Unit costs of health and social care. Canterbury: PSSRU, 1999. 168. Renehan AG, O’Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ 2004;328:81. 169. Primrose J, Mant D. FACS – a randomised controlled trial to access the cost-effectiveness of intensive versus scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent. Trial protocol. University of Southampton, 2004. 170. Hospital episode statistics (2003/04), 2004. URL: http://www.hesonline.nhs.uk/. Accessed 12 January 2005. 171. Aventis Pharma Ltd. Submission to the National Institute for Clinical Excellence on Campto (irinotecan) for advanced colorectal cancer – irinotecan, oxaliplatin and raltitrexed (review). Aventis Pharma Ltd, UK; 2004. 172. Smith RD, Hall J, Gurney H, Harnett PR. A cost–utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes’ C colonic carcinoma. Med J Aust 1993; 158:319–22. 173. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes’ B and C colorectal carcinoma: a costeffectiveness analysis. Ann Oncol 1997;8:65–70. 174. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999;94:1650–7. 175. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long-term survivors of colorectal cancer. Am J Gastroenterol 2002;97:1228–34. 176. Petrou S, Campbell N. Stabilisation in colorectal cancer. Int J Palliat Nurs 1997;3:275–80. 177. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8 Suppl 1:S41–53. 178. Berg D. Oxaliplatin: a novel platinum analog with activity in colorectal cancer. Oncol Nurs Forum 2003;30:957–66. 179. Gerbrecht BM, Kangas T. Implications of capecitabine (Xeloda) for cancer nursing practice. Eur J Oncol Nurs 2004;8 Suppl 1:S63–71. 180. Corner J. The role of nurse-led care in cancer management. Lancet Oncol 2003;4:631–6. 181. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Nat Cancer Inst 2002;94:652–61. 182. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. J Clin Oncol 2004 ASCO Annu Meet Proc (Post-Meet Ed) 2004;22:Abstract No. 3500. 183. Van Cutsem E, Labianca D, Hossfield G, Bodoky A, Roth E, Aranda B, et al. Randomised phase III trial comparing infused irinotecan/5-fluorouracil (F) in stage III colon cancer (pts). ASCO Annual Meeting – Gastrointestinal (Colorectal) Cancer, 2005; Abstract No. LBA8. 184. Ychou M, Raoul J, Douillard R, Bugat L, Mineur F, Viret Y, et al. A phase III randomised trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). ASCO Annual Meeting – Gastrointestinal (Colorectal) Cancer; 2005; Abstract No. 3502. 185. Glynne-Jones R. CHRONICLE – chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer. A randomised phase III trial of control vs capecitabine plus oxaliplatin: trial protocol. Cancer Research UK & UCL Cancer Trials Centre, 2005. 186. Matasar MJ, Sundararajan V, Grann VR, Neugut AI. Management of colorectal cancer in elderly patients – focus on the cost of chemotherapy. Drugs Aging 2004;21:113–33. 187. Schmoll HJ, Tabernero J, Nowacki M, Maroun J, Figer A, Price T, et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs bolus 5-FU/LV as adjuvant therapy for patients with stage III colon cancer. ASCO Annual Meeting, 2005; Abstract No. 3523. 188. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (reference N0515). London: NICE: 2004. URL: http://www.nice.org.uk/. Accessed 3 June 2005. 189. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand–foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer Invest 2002;20:3–10. 190. Anonymous. Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer. Cancer Treat Rev 2004;30:711–13. 191. Anonymous. Oxaliplatin shows significant benefit over standard therapy in early-stage colon cancer. Oncology (Huntington) 2004;18:1313. 192. Anonymous. Efficacy, safety, and cost of new anticancer drugs. Prescrire Int 2003;12:33–5. 193. Arkenau HT, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma. Verdauungskrankheiten 2004;22:208–15. 194. Bleiberg H. Adjuvant therapy in high-risk colon cancer. Semin Oncol 2000;27:48–59. 195. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 2001;6:12–16. 196. Brezault C, Giacchetti S, Zidanli R, Tigaud JM, Levi F. Continuous chemotherapy in colorectal cancer. Oncologie 1999;1:304–10. 197. Cascinu S, Labianca R, Daniele B, Beretta G, Salvagni S. Survival and quality of life in gastrointestinal tumors: two different end points? Ann Oncol 2001;12:S31–6. 198. Cascinu S, Munao S, Mare M, Amadio P, Crucitta E, Picone G. Tolerability profile of platinum drugs. Tumori 2000;86:S54–5. 199. Conroy T, Blazeby JM. Health-related quality of life in colorectal cancer patients. Expert Rev Anticancer Ther 2003;3:493–504. 200. de Gramont A, Andre T, Hickish T. Oxaliplatin in colon cancer. N Engl J Med 2004;351:1691–2. 201. Dogliotti L, Garufi C, Iacobelli S. Chronochemotherapy in colorectal cancer. Tumori 2000;86:S32–6. 202. Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003;14:497–8. 203. Goldberg RM, Saltz L, Grem JL, Lenz HJ, Ajani JA, Blackstock AW, et al. Oxaliplatin in colorectal cancer: new data in first-line and adjuvant therapy. Onkologie 2002;25:1–11. 204. Goodman A. ‘Compelling’ interim data favoring use of oxaliplatin in colorectal cancer. Oncol Times 2002;24:9–10. 205. Kullmann F. Capecitabin (Xeloda). Padiatr Praxis 2003;63:151–7. 206. Kullmann, F. Capecitabin (Xeloda). Gynakol Praxis 2003;27:351–8. 207. Kullmann F. Capecitabin (Xeloda). Internist Praxis 2003;43:415–21. 208. Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, et al. Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J N Cancer Inst 2004;96:750–8. 209. Laino C. Colorectal cancer: oxaliplatin-based combos improve outcome. Oncol Times 2003; Special Edition; 4–5. 210. Mandala M, Ferretti G, Barni S. Oxaliplatin in colon cancer. N Engl J Med 2004;351:1691–2. 211. Maung K, Chu E, Jain VK. Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer. Clin Colorectal Cancer 2003; 3:150–3. 212. National Horizon Scanning Centre. Oxaliplatin, irinotecan and capecitabine as adjuvant therapy in colorectal cancer. 2003. URL: http://www.pcpoh.bham.ac.uk/publichealth/ horizon/technology.htm. Accessed 1 November 2004. 213. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282–308. 214. Reddy GK, Chu E. Efficacy of adjuvant capecitabine compared with bolus 5- fluorouracil/leucovrin regimen in Dukes C colon cancer: results from the X-ACT trial. Clin Colorectal Cancer 2004;4:87–8. 215. Sorich J, Taubes B, Wagner A, Hochster H. Oxaliplatin: practical guidelines for administration. Clin J Oncol Nurs 2004;8:251–6. 216. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97:2301–7. 217. Tisman G, MacDonald D, Shindell N, Reece E, Patel P, Honda N, et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 2004;22:3202–4. 218. Wils J, O’Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century European and US perspectives. Ann Oncol 2001; 12:13–22. 219. Zaniboni A. Adjuvant treatment of colon carcinoma. Tumori 2000;86:S23–4. 220. Zeuli M, Pino MS, Cognetti F. Capecitabine in the treatment of colorectal cancer. Tumori 2001; 87:S55–6. 221. Cairns JA, van der Pol MM. The estimation of marginal time preference in a UK-wide sample (TEMPUS) project. Health Technol Assess 2000;4(1). 222. Bonistalli L, Bardelli F, Costantini M, Trallori G, d’Albasio G, Messori A. Adjuvant chemotherapy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis. Cancer 1998;11:39–47. 223. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for Stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Nat Cancer Inst 1994;86:424–30. 224. Jansman FGA, Postma MJ, van Hartskamp D, Willemse PHB, Brouwers JRBJ. Cost–benefit analysis of capecitabine versus 5-fluorouracil/ leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004;26:579–89. 225. Macdonald JS. Adjuvant therapy for colon cancer. CA Cancer J Clin 1997;47:243–56. 226. Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. J Clin Gastroenterol 1996;23:269–74. 227. Michel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, et al. Postoperative management of stage II/III colon cancer: a decision analysis. Gastroenterology 1999;117:784–93.
URI:	http://wrap.warwick.ac.uk/id/eprint/46336

Request changes to a record

Actions (login required)

View Item